Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;227(11):1293–1302. doi: 10.1093/infdis/jiac481

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Box plots of individual data for CD4⁺ T cells (per million CD4⁺ T cells) expressing T-helper 2 (Th2) profile on stimulation with respiratory syncytial virus (RSV) peptide pools (fusion [F], nucleoprotein [N], and matrix [M2-1]), through day 366 after baseline (day 1; per-protocol set). Th2 cells are CD4⁺ T cells expressing at least interleukin 13 but not interferon γ. Abbreviations: HD, LD, and MD, high, low, and medium dosage of the RSV investigational vaccine or placebo; Q1, quarter 1; Q3, quarter 3. Graph shows data at each time point for the following numbers of participants: RSV-LD, 3–9; RSV-MD, 0–3; RSV-HD, 0–1; placebo-LD, 4–10; placebo-MD, 0–2; placebo-HD, 0–1.